Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

When fat goes down, prostate cancer is on the ropes.

Zadra G, Loda M.

Mol Cell Oncol. 2019 Apr 16;6(3):1595308. doi: 10.1080/23723556.2019.1595308. eCollection 2019.

PMID:
31131311
2.

Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging.

Randall EC, Zadra G, Chetta P, Lopez BGC, Syamala S, Basu SS, Agar JN, Loda M, Tempany CM, Fennessy FM, Agar NYR.

Mol Cancer Res. 2019 May;17(5):1155-1165. doi: 10.1158/1541-7786.MCR-18-1057. Epub 2019 Feb 11.

PMID:
30745465
3.

Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.

Zadra G, Ribeiro CF, Chetta P, Ho Y, Cacciatore S, Gao X, Syamala S, Bango C, Photopoulos C, Huang Y, Tyekucheva S, Bastos DC, Tchaicha J, Lawney B, Uo T, D'Anello L, Csibi A, Kalekar R, Larimer B, Ellis L, Butler LM, Morrissey C, McGovern K, Palombella VJ, Kutok JL, Mahmood U, Bosari S, Adams J, Peluso S, Dehm SM, Plymate SR, Loda M.

Proc Natl Acad Sci U S A. 2019 Jan 8;116(2):631-640. doi: 10.1073/pnas.1808834116. Epub 2018 Dec 21.

4.

Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Elfandy H, Armenia J, Pederzoli F, Pullman E, Pertega-Gomes N, Schultz N, Viswanathan K, Vosoughi A, Blattner M, Stopsack KH, Zadra G, Penney KL, Mosquera JM, Tyekucheva S, Mucci LA, Barbieri C, Loda M.

Mol Cancer Res. 2019 Feb;17(2):446-456. doi: 10.1158/1541-7786.MCR-18-0440. Epub 2018 Oct 17.

PMID:
30333152
5.

Specific 18F-FDHT Accumulation in Human Prostate Cancer Xenograft Murine Models Is Facilitated by Prebinding to Sex Hormone-Binding Globulin.

Larimer BM, Dubois F, Bloch E, Nesti S, Placzek M, Zadra G, Hooker JM, Loda M, Mahmood U.

J Nucl Med. 2018 Oct;59(10):1538-1543. doi: 10.2967/jnumed.118.208785. Epub 2018 May 31.

PMID:
29853654
6.

Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.

Zadra G, Loda M.

Cold Spring Harb Perspect Med. 2018 Oct 1;8(10). pii: a030569. doi: 10.1101/cshperspect.a030569. Review.

PMID:
29229664
7.

MYC Overexpression at the Protein and mRNA Level and Cancer Outcomes among Men Treated with Radical Prostatectomy for Prostate Cancer.

Pettersson A, Gerke T, Penney KL, Lis RT, Stack EC, Pértega-Gomes N, Zadra G, Tyekucheva S, Giovannucci EL, Mucci LA, Loda M.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):201-207. doi: 10.1158/1055-9965.EPI-17-0637. Epub 2017 Nov 15.

8.

Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer.

Ebot EM, Gerke T, Labbé DP, Sinnott JA, Zadra G, Rider JR, Tyekucheva S, Wilson KM, Kelly RS, Shui IM, Loda M, Kantoff PW, Finn S, Vander Heiden MG, Brown M, Giovannucci EL, Mucci LA.

Cancer. 2017 Nov 1;123(21):4130-4138. doi: 10.1002/cncr.30831. Epub 2017 Jul 12.

9.

Metabolic Profiling in Formalin-Fixed and Paraffin-Embedded Prostate Cancer Tissues.

Cacciatore S, Zadra G, Bango C, Penney KL, Tyekucheva S, Yanes O, Loda M.

Mol Cancer Res. 2017 Apr;15(4):439-447. doi: 10.1158/1541-7786.MCR-16-0262. Epub 2017 Jan 10.

10.

Dissecting the Dual Role of AMPK in Cancer: From Experimental to Human Studies.

Zadra G, Batista JL, Loda M.

Mol Cancer Res. 2015 Jul;13(7):1059-72. doi: 10.1158/1541-7786.MCR-15-0068. Epub 2015 May 8. Review.

11.

Role of diet in prostate cancer: the epigenetic link.

Labbé DP, Zadra G, Ebot EM, Mucci LA, Kantoff PW, Loda M, Brown M.

Oncogene. 2015 Sep 3;34(36):4683-91. doi: 10.1038/onc.2014.422. Epub 2014 Dec 22. Review.

12.

AKT1 and MYC induce distinctive metabolic fingerprints in human prostate cancer.

Priolo C, Pyne S, Rose J, Regan ER, Zadra G, Photopoulos C, Cacciatore S, Schultz D, Scaglia N, McDunn J, De Marzo AM, Loda M.

Cancer Res. 2014 Dec 15;74(24):7198-204. doi: 10.1158/0008-5472.CAN-14-1490. Epub 2014 Oct 16.

13.

A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis.

Zadra G, Photopoulos C, Tyekucheva S, Heidari P, Weng QP, Fedele G, Liu H, Scaglia N, Priolo C, Sicinska E, Mahmood U, Signoretti S, Birnberg N, Loda M.

EMBO Mol Med. 2014 Apr;6(4):519-38. doi: 10.1002/emmm.201302734. Epub 2014 Feb 4. Erratum in: EMBO Mol Med. 2014 Oct;6(10):1357.

14.

De novo fatty acid synthesis at the mitotic exit is required to complete cellular division.

Scaglia N, Tyekucheva S, Zadra G, Photopoulos C, Loda M.

Cell Cycle. 2014;13(5):859-68. doi: 10.4161/cc.27767. Epub 2014 Jan 13.

15.

The fat side of prostate cancer.

Zadra G, Photopoulos C, Loda M.

Biochim Biophys Acta. 2013 Oct;1831(10):1518-32. doi: 10.1016/j.bbalip.2013.03.010. Epub 2013 Apr 2. Review.

16.

Metabolic alterations and targeted therapies in prostate cancer.

Flavin R, Zadra G, Loda M.

J Pathol. 2011 Jan;223(2):283-94. doi: 10.1002/path.2809. Epub 2010 Nov 16. Review.

17.

New strategies in prostate cancer: targeting lipogenic pathways and the energy sensor AMPK.

Zadra G, Priolo C, Patnaik A, Loda M.

Clin Cancer Res. 2010 Jul 1;16(13):3322-8. doi: 10.1158/1078-0432.CCR-09-1955. Epub 2010 Apr 27. Review.

18.

Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors.

Vaira V, Fedele G, Pyne S, Fasoli E, Zadra G, Bailey D, Snyder E, Faversani A, Coggi G, Flavin R, Bosari S, Loda M.

Proc Natl Acad Sci U S A. 2010 May 4;107(18):8352-6. doi: 10.1073/pnas.0907676107. Epub 2010 Apr 19.

19.

Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer.

Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M.

J Natl Cancer Inst. 2009 Apr 1;101(7):519-32. doi: 10.1093/jnci/djp030. Epub 2009 Mar 24.

20.

Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer.

Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M.

Lab Invest. 2008 Dec;88(12):1340-8. doi: 10.1038/labinvest.2008.97. Epub 2008 Oct 6.

21.

Simultaneous genotyping of coagulation factor XI type II and type III mutations by multiplex real-time polymerase chain reaction to determine their prevalence in healthy and factor XI-deficient Italians.

Zadra G, Asselta R, Tenchini ML, Castaman G, Seligsohn U, Mannucci PM, Duga S.

Haematologica. 2008 May;93(5):715-21. doi: 10.3324/haematol.12180. Epub 2008 Apr 2.

22.

Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord.

Gorio A, Madaschi L, Zadra G, Marfia G, Cavalieri B, Bertini R, Di Giulio AM.

J Pharmacol Exp Ther. 2007 Sep;322(3):973-81. Epub 2007 Jun 29.

PMID:
17601981
23.

Survivin expression in tuberous sclerosis complex cells.

Carelli S, Lesma E, Paratore S, Grande V, Zadra G, Bosari S, Di Giulio AM, Gorio A.

Mol Med. 2007 Mar-Apr;13(3-4):166-77.

24.

Up-regulation of focal adhesion kinase in non-small cell lung cancer.

Carelli S, Zadra G, Vaira V, Falleni M, Bottiglieri L, Nosotti M, Di Giulio AM, Gorio A, Bosari S.

Lung Cancer. 2006 Sep;53(3):263-71. Epub 2006 Jul 13.

PMID:
16842883
25.

Molecular genetic analysis of severe coagulation factor XI deficiency in six Italian patients.

Zadra G, Asselta R, Malcovati M, Santagostino E, Peyvandi F, Mannucci PM, Tenchini ML, Duga S.

Haematologica. 2004 Nov;89(11):1332-40.

Supplemental Content

Support Center